antibody

HCK Polyclonal Antibody

MBS126978

0.05 mg

230 USD

polyclonal

rabbit

nonconjugated

human, mouse, rat

western blot, immunohistochemistry, immunocytochemistry

Antibody

HCK Polyclonal Antibody

HCK

JTK9

Tyrosine-protein kinase HCK; Tyrosine-protein kinase HCK; tyrosine-protein kinase HCK; p59-HCK/p60-HCK; hemopoietic cell kinase; hematopoietic cell kinase; HCK proto-oncogene, Src family tyrosine kinase; Hematopoietic cell kinase; Hemopoietic cell kinase; p59-HCK/p60-HCK; p59Hck; p61Hck

HCK

HCK; HCK; JTK9; p59Hck; p61Hck

HCK_HUMAN

Polyclonal

IgG

Rabbit

Human, Mouse, Rat

526

Affinity Purification

1mg/ml

Store at -20 degree C (regular) or -80 degree C (long term). Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)

WB: 1:500 - 1:2000. IHC: 1:50 - 1:200

Species: Human. Route: Recombinant Protein

Immunogen: Recombinant protein of human HCK. Calculated Molecular Weight: 57kDa

Polyclonal

Hck (hemopoietic cell kinase) is a protein tyrosine kinase of the Src family prominently expressed in the lymphoid and myeloid lineages of hemopoiesis (1). It participates in transducing a variety of extracellular signals, which ultimately affect cellular processes including proliferation, differentiation and migration.The well-defined modular structure of Hck comprises a relatively divergent, NH2-terminal "unique" domain, which is subject to post-translational lipid modifications thereby targeting Hck to the plasma membrane. Src homology 3 (SH3) and 2 (SH2) domains, and a tyrosine kinase catalytic domain follow the "unique" domain. The catalytic activity of Hck is regulated, both positively and negatively, by tyrosine phosphorylation of highly conserved tyrosine (Y) residues. Phosphorylation of a single conserved Tyr499 residue in the COOH terminus of Hck by the protein kinase Csk renders Hck inactive as a result of an intramolecular interaction between the phosphorylated tyrosine (pY) residue and its own SH2 domain. Disruption of this interaction, either as a result of dephosphorylation, or substitution of the COOH-terminal regulatory Y residue with phenylalanine (F; e.g., HckY499F), or COOH-terminal truncation mutations as observed in the virally transduced v-Src oncoprotein, results in constitutive activation of Hck. In contrast to phosphorylation of the COOH-terminal regulatory tyrosine residue, autophosphorylation of a tyrosine residue (Tyr388) within the kinase domain of Hck acts to positively regulate its catalytic activity. Thus, activation of Hck requires both disruption of the COOH-terminal regulatory tyrosine-SH2 domain interaction and autophosphorylation of the regulatory tyrosine residue within the kinase domain (2, 3). The dysfunction or dysregulation of Hck may contribute to the pathogenesis of some human leukemias (4).

20141296

P08631.5

P08631

526

Alpha-synuclein Signaling Pathway 137913!!B Cell Receptor Signaling Pathway 198909!!CXCR4-mediated Signaling Events Pathway 137910!!Chemokine Signaling Pathway 99051!!Chemokine Signaling Pathway 96864!!Class I PI3K Signaling Events Pathway 138022!!Cytokine Signaling In Immune System Pathway 366171!!Disease Pathway 530764!!EPHA Forward Signaling Pathway 138041!!Ephrin B Reverse Signaling Pathway 138052

The protein encoded by this gene is a member of the Src family of tyrosine kinases. This protein is primarily hemopoietic, particularly in cells of the myeloid and B-lymphoid lineages. It may help couple the Fc receptor to the activation of the respiratory burst. In addition, it may play a role in neutrophil migration and in the degranulation of neutrophils. Multiple isoforms with different subcellular distributions are produced due to both alternative splicing and the use of alternative translation initiation codons, including a non-AUG (CUG) codon. [provided by RefSeq, Feb 2010]

0.05 mg

230 USD